Description
The TH9 antibody monoclonal antibody specifically binds to CD59, a 21 kDa glycosyl-phosphatidyl inositol-anchored cell-surface glycoprotein of the Ly-6 superfamily. CD59 is expressed by many types of non-hematopoietic cells. In the rat hematopoietic system, CD59 has been detected on erythrocytes, monocytes, and some lymphocytes, but not on platelets. Soluble CD59 is found in body fluids and urine. CD59 is a complement regulatory protein that acts late in the complement cascade to prevent formation of the membrane attack complex (MAC). Therefore, CD59 is one of several proteins whose function is to protect host tissue from complement attack. Rat CD59 binds rat and human complement components and inhibits cytolysis mediated by complement from multiple species. CD59 has also been suggested to be a ligand for CD2 and to participate in T-cell costimulation.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please observe the following precautions: Absorption of visible light can significantly alter the energy transfer occurring in any tandem fluorochrome conjugate; therefore, we recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to prevent exposure of conjugated reagents, including cells stained with those reagents, to room illumination.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
5. An isotype control should be used at the same concentration as the antibody of interest.
6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
7. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
8. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
9. Researchers should determine the optimal concentration of this reagent for their individual applications.
